With the F.D.A. agreeing to new trials to test MDMA (better known as Ecstasy) as a treatment for PTSD—which, if approved, could be available as a drug by 2021—Acid Test is leading the charge in an evolving conversation about psychedelic drugs.
Though researchers are still trying to understand the cognitive and therapeutic mechanics of psychedelics, they have concluded that psilocybin, DMT and other psychoactive chemicals can help people feel more tolerance, understanding and empathy.
Psychedelics afford a unique opportunity to expand our understanding of consciousness and its altered states, to develop techniques for enhancing consciousness, and to uncover new avenues of treatment and improved therapeutic techniques.
Explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics • Explores the tumultuous history of psychedelic research, the efforts to restore psychedelic therapies, and the links between psychiatric drugs and mental illness • Offers...
After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction.
Recently, there has been much excitement in the potential of psychedelic-assisted psychotherapy to address a multitude of mental health conditions, including depression, posttraumatic stress disorder, addiction, end-of-life anxiety, and others. However, not everyone has been included.
We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.